Medical Cannabis Has Passed Peak Hype and Is Moving Toward Realistic Clinical Application

Medical cannabis research surged in the mid-to-late 2010s, but measured clinical benefits are generally modest, vary by product/dose/population, and are limited by research challenges including heterogeneity and blinding difficulties. The field is progressing from inflated expectations toward realistic therapeutic goals, standardized products, and systematic safety attention.

Narrative review synthesizing clinical evidence on medical cannabis through the lens of the Gartner Hype Cycle technology adoption framework. Reviews therapeutic evidence, identifies current limitations, and proposes paths forward for the field.

The hype cycle framework helps explain the whiplash many have experienced with medical cannabis -- from "miracle cure" enthusiasm to "it doesn't work" skepticism. Recognizing where the field is on this cycle allows for more productive conversations about realistic expectations and research priorities.

Many breakthrough technologies and therapies follow the hype cycle pattern. The maturation of medical cannabis from overpromising to evidence-based application mirrors the trajectory of other medical innovations. The critical next steps are head-to-head trials against existing treatments and standardized products that enable reproducible research.

The hype cycle is a descriptive framework, not a predictive model. Narrative reviews are inherently subject to author perspective. The field is evolving rapidly, and the review may not capture the most recent developments.